All items in the Healthy Skepticism Library
All the 20545 items in the Healthy Skepticism Library are listed below in order of publication date with the most recent at the top. There are 100 items per page.
Page 153 of 206 pages ‹ First < 151 152 153 154 155 > Last ›
HSL10421
Hughes I.
Let us hope a door may be opened to further discussion - Campaign summary
Pharmaceutical Journal 2003;270:(7251):750-751
HSL10422
Omeprazole to be a pharmacy medicine
Pharmaceutical Journal 2003;270:(7250):709
HSL10423
Seligman PJ.
'Dear doctor....' - Evaluating the impact of risk communication efforts
Pharmacoepidemiology and Drug Safety 2003;12:(4):291-293
HSL10427
Arbuckle JBR.
Supply of POMs
Veterinary Record 2003;152:(21):667-668
HSL10428
Medicines in Europe campaign
Prescrire International 2003;12:(65):115
HSL10430
Major therapeutic advances are rare
Prescrire International 2003;12:(63):31
HSL10431
A needless addition to the other macrolides
Prescrire International 2003;12:(63):8-11
HSL10467
Medicines Australia Code of Conduct
Australian Prescriber 2003;26:(3):66
HSL10468
Topical use of Lindane
WHO Drug Information 2003;17:(1):26-28
HSL10469
Richardson R, Shaw I, Nolan S.
A perspective on New Zealand's medicines regulatory environment
International Journal of Pharmaceutical Medicine 2003;17:(1):17-22
HSL10471
George Wong HC
Potential reactions to patent medicines containing prescription drugs
Allergy and Clinical Immunology International 2003;15:(3):114-118
HSL10476
First statin patent expires amid OTC speculation
Pharmaceutical Journal 2003;270:(7247):603
HSL10477
Pharmacists believe EHC is too costly
Pharmaceutical Journal 2003;270:(7247):603
HSL10478
From the supply of POMs to proposed changes in the BVA'S structure
Veterinary Record 2003;152:(19):575-578
HSL10479
OFT acts on the supply of POMs
Veterinary Record 2003;152:(19):574
HSL10480
Schulze J, Raasch W, Siegers CP.
Toxicity of kava pyrones, drug safety and precautions--a case study.
Phytomedicine 2003;10:
HSL10484
New therapies drive up cost of GI medications
Drug Benefit Trends 2003;15:6-7
HSL10498
Bad medicine
Veterinary Record 2003;152:(16):481
HSL10499
Vet medicines monopoly to be broken
Pharmaceutical Journal 2003;270:(7245):534
HSL10500
Cheng JWM.
Bosentan
Heart Disease 2003;5:(2):161-169
HSL10504
How genetics could change pharmacy
Pharmaceutical Journal 2003;270:(7244):508-509
HSL10505
Medicine imports and exports rising
Pharmaceutical Journal 2003;270:(7244):501
HSL10506
Hemels MEH, Bennett HA, Bonari L, Han D, Traverso ML, Einarson TR.
HOPE study impact on ACE inhibitors use
Annals of Pharmacotherapy 2003;37:(5):640-645
HSL10507
Maskrey N, Jackson C, Critchlow H.
Support to consider the resource implications of NICE guidance
Journal of Clinical Excellence 2003;4:(3):306-309
HSL10508
Toop L, Richards D, Dowell T.
The leadership role of general practice in public health: advocating a ban of direct-to-consumer advertising of prescription drugs in New Zealand; 'Possums in the headlights?'.
British Journal of General Practice 2003;53:(489):342-345
http://www.ingentaconnect.com/content/rcgp/bjgp/2003/00000053/00000489;jsessionid=1dei97cpjj6ai.henrietta?
HSL10510
Wolfe SH.
Ephedra - Scientific evidence versus money/politics
Science 2003;300:(5618):437
HSL10511
Slade RFJ.
Why the change from 14-disk to 15-disk packs? [3]
Pharmaceutical Journal 2003;270:(7243):476
HSL10512
DTB advocates prescription of injectable adrenaline for children
Pharmaceutical Journal 2003;270:(7242):427
HSL10514
Manufacturer claims superior action for new statin
Pharmaceutical Journal 2003;270:(7242):427
HSL10515
Supplementary prescribing legal from next week
Pharmaceutical Journal 2003;270:(7242):424
HSL10517
Links.
Compliance Policy Guide on Chapter 4 Human Drugs: Section 460.200 Pharmacy Compounding.
J Pain Palliat Care Pharmacother 2003;17:(1):99-106
HSL10518
Hildebrand JR.
Report from the USA
Pharmazeutische Industrie 2003;65:(3):247-251
HSL10520
Theodorou AA.
How 3-tier plan design and other strategies yielded $1.6 billion in cost savings
Drug Benefit Trends 2003;15:(3):45-54
HSL10521
IJPP given a new look and is now fully available online
Pharmaceutical Journal 2003;270:(7241):410-411
HSL10522
Armendariz M, Armendariz M, Jaio N, Gorostiza I.
Impact of new non-steroid anti-inflammatory drugs in Primary Care prescription
Pharmaceutical Care Espana 2003;5:(1):29-38
HSL10523
Roy V, Goyal RK.
Of societies and issues (multiple letters)
Indian Journal of Pharmacology 2003;35:(2):116-118
http://www.doaj.org/openurl?genre=article&issn=0253-7613&volume=35&issue=2&spage=116
HSL10524
Lam W.
Off-label promotion and prescribing of gabapentin [2]
Australian Prescriber 2003;26:(2):28
HSL10525
Krznaric Z.
Drugs in gastroenterology
Medicus 2003;11:(1):67-78
HSL10530
Achanta AS.
OTC switch case history evaluation: NicoretteR
Clinical Research and Regulatory-Affairs 2003;20:(1):15-26
HSL10531
Schmidt RJ.
Generic specifications for standard products needed [16]
Pharmaceutical Journal 2003;270:(7233):116-117
HSL10532
Scrap contract regulations, says OFT
Pharmaceutical Journal 2003;270:(7233):103
HSL10533
Dismal science sells pharmacy short
Pharmaceutical Journal 2003;270:(7233):102
HSL10534
Eberwein B, Schulz R.
Allensbach study phytopharmaceutics in 2002, part 2
Schweizerische Zeitschrift fur GanzheitsMedizin 2003;15:(2):87-93
HSL10536
Boots keeps its spot as biggest health retailer in Europe
Pharmaceutical Journal 2003;270:(7240):360
HSL10537
Simmonds H.
The role of the PMCPA explained [13]
Pharmaceutical Journal 2003;270:(7239):334-335
HSL10541
Robinson K.
A rocky road for generics
BioPharm International 2003;16:(1):24-26
HSL10542
Moulds RFW.
Good prescribing: Where to next?
Medical Journal of Australia 2003;178:(5):196-197
HSL10544
Wade OL.
The British National Formulary - Memoirs of a former chairman
Pharmaceutical Journal 2003;270:(7237):278-281
HSL10545
Kempner N.
Planning ahead: Are customers sick of smoking?
Pharmaceutical Journal 2003;270:(7237):273
HSL10546
McNulty H.
Putting children first [19]
Pharmaceutical Journal 2003;270:(7237):269
HSL10547
Mason J.
Is the marketing of pharmaceuticals a matter of style over substance?
Pharmaceutical Journal 2003;270:(7237):264
HSL10620
Neto A.
Changing pharmacy practice: The Australian experience
Pharmaceutical Journal 2003;270:(7236):235-236
HSL10623
Murthy JMK.
Some problems and pitfalls in developing countries
Epilepsia 2003;44:(1):38-42
http://www.blackwell-synergy.com/rd.asp?code=EPI&vol=44&page=38&goto=abstract
HSL10625
Cox AR.
Prescribers need appraisal training programmes [21]
Pharmaceutical Journal 2003;270:(7234):154
HSL10626
Antiepileptics for migraine prophylaxis only cost-effective with frequent episodes
Expert Review of Pharmacoeconomics and Outcomes Research 2003;3:(1):5-12
HSL10633
Sweet M.
Gabapentin documents raise concerns about off-label promotion and prescribing
Australian Prescriber 2003;26:(1):18-19
HSL10635
Dooley M.
Prescribing of warfarin, and brand selection [2]
Journal of Pharmacy Practice and Research 2003;32:(4):259+261
HSL10636
Lubliner AA.
Are over-the-counter St. John's wort preparations as effective as assumed?
Deutsche Apotheker Zeitung 2003;143:(1-2):50-52
HSL10638
Call for schering to repay NHS money over Yasmin claims
Pharmaceutical Journal 2003;270:(7231):42
HSL10639
Pharmaceutical industry promotions criticised
Pharmaceutical Journal 2003;270:(7231):42
HSL10644
Lucioni C, Mazzi S.
Prescription practice versus consuption standards with reference to proton pump inhibitors in Italy
PharmacoEconomics - Italian Research Articles 2003;5:(1):3-10
HSL10645
Palmer JBD, Palmer RH.
Alosetron for irritable bowel syndrome [9] (multiple letters)
British Medical Journal 2003;326:(7379):51-52
HSL10646
A measured response on medicines
Veterinary Record 2003;152:(1):1-2
HSL10647
Thompson M.
Trends in claims for pharmacists' errors
Pharmaceutical Journal 2003;270:(7230):
HSL10648
Drug price competition has little effect on NHS buying, PPRS study finds
Pharmaceutical Journal 2003;270:(7230):
HSL11549
Miller D, Dinan W.
Global public relations and global capitalism
Demers D. Terrorism, Globalization and Mass Communication Spokane, WA: Marquette Books 2003
http://www.amazon.com/Terrorism-Globalization-Mass-Communication-Conference/dp/0922993041/ref=sr_1_1/102-5869202-0212934?ie=UTF8&s=books&qid=1190546162&sr=1-1
HSL11748
Reaves ND.
A model of effective health policy: the 1983 Orphan Drug Act.
J Health Soc Policy 2003;17:(4):61-71
http://www.ncbi.nlm.nih.gov/sites/entrez?Db=PubMed&Cmd=ShowDetailView&TermToSearch=17824591
HSL13205
Auvray L, Hensgen F, Sermet C.
La diffusion de l'innovation pharmaceutique en médecine libérale : revue de la littérature et premiers résultats français [Diffusion of pharmaceutical innovation in liberal medicine: revue of literature and first French results.]
Quest écon santé 2003;73:1-8
http://cat.inist.fr/?aModele=afficheN&cpsidt=15305034
HSL13263
Bero L.
Implications of the tobacco industry documents for public health and policy.
Annu Rev Public Health 2003;24:267-88
http://arjournals.annualreviews.org/doi/abs/10.1146%2Fannurev.publhealth.24.100901.140813
HSL13294
Mehrotra A, Dudley RA, Luft HS.
What's behind the health expenditure trends?
Annu Rev Public Health 2003;24:385-412:
http://arjournals.annualreviews.org/doi/abs/10.1146%2Fannurev.publhealth.24.100901.141008
HSL16001
Nascimento A.
“AO PERSISTIREM OS SINTOMAS O MÉDICO DEVERÁ SER CONSULTADO”. ISTO É REGULAÇÃO?
INSTITUTO DE MEDICINA SOCIAL RIO DE JANEIRO: UNIVERSIDADE DO ESTADO DO RIO DE JANEIRO 2003
Http://www4.ensp.fiocruz.br/visa/publicacoes/_arquivos/DissertacaoPropagandadeMedicamentos.doc
HSL16334
Blech J
Les inventeurs de maladies. Manœuvres et manipulations de l’industrie pharmaceutique. Paris: Actes Sud 2003
http://martinwinckler.com/article.php3?id_article=577
HSL16339
Greider K
The Big Fix: How the pharmaceutical industry rips off American consumers New York: Public Affairs 2003
http://www.amazon.com/Big-Fix-Pharmaceutical-Consumers-Publicaffairs/dp/1586481851
HSL16343
Healy D
Let them eat Prozac. Toronto: Lorrimer 2003
http://books.google.com.au/books?id=5w64WC_-jbMC&dq=Healy,+David.+Let+them+eat+Prozac.&printsec=frontcover&source=bn&hl=en&ei=g5yYSuG8DpKUkAWstsWrAg&sa=X&oi=book_result&ct=result&resnum=4#v=onepage&q=&f=false
HSL16348
Pignarre P
Le grand secret de l’industrie pharmaceutique Paris: La Découverte 2003
http://www.amazon.fr/grand-secret-lindustrie-pharmaceutique/dp/2707144398
HSL16924
Nascimento AC
'Ao persistirem os sintomas o médico deverá ser consultado'. Isto é regulação?
Instituto de Medicina Social da Universidade do Estado do Rio de Janeiro 2003;
http://www.scielo.br/scielo.php?pid=S0102-311X2006001200023&script=sci_arttext
HSL17363
Egilman D, Kim J, Biklen M.
Proving causation: the use and abuse of medical and scientific evidence inside the courtroom--an epidemiologist's critique of the judicial interpretation of the Daubert ruling.
Food Drug Law J 2003;58:(2):223-50
http://www.ncbi.nlm.nih.gov/pubmed/12866555
HSL17715
Mahowald M, Bornemann M
Psychological aspects of gifts from drug companies
JAMA 2003;298:(18):2404-2405
HSL17966
Bromley E, Metzl JM
Book Reviews: Prozac on the Couch: Prescribing Gender in the Era of Wonder Drugs : Duke University Press 2003
HSL18060
Smethurst D
Pharmaceutical medicine: making the leap
BMJ 2003;327:s161-s162
http://archive.student.bmj.com/issues/04/02/careers/66.php
HSL18063
Moynihan R
Cochrane launches global consultation on drug company sponsorship
BMJ 2003;327:(7423):1068
http://www.bmj.com/cgi/content/full/327/7423/1068
HSL18065
Dyer O
Lancet accuses AstraZeneca of sponsoring biased research
BMJ 2003;327:(7422):1005
http://www.bmj.com/cgi/content/full/327/7422/1005-a
HSL18073
Relman A
Book review :Magic Cancer Bullet: How a Tiny Orange Pill Is Rewriting Medical History by Daniel Vesella
JAMA 2003;290:(16):2194
http://jama.ama-assn.org/cgi/content/full/290/16/2194
HSL18111
Lynden B
Withdrawal of useful drugs from the market
Aust Prescr 2003;26:50-1
http://www.australianprescriber.com/index.php?content=/magazines/vol26no3/50_51_editorial.htm
HSL18113
Dowden J
The story of one complaint
Aust Prescr 2003;26:(3):
http://www.australianprescriber.com/index.php?content=/magazines/vol26no3/67_complaint.htm
HSL18176
Fava GA
Conflict of interest and the credibility of medical journals
Psychotherapy and Psychosomatics 2003;12:1
HSL18185
Seaton A
Personal Views: 'There's none so blind as the double blind'.
BMJ 2003;326:(7394):889
http://www.bmj.com/cgi/content/full/326/7394/889
HSL18190
Rector TS, Finch MD, Danzon, PM, Pauly MV, Manda BS
Effect of Tiered Prescription Copayments on the Use of Preferred Brand Medications
Medical Care 2003;
http://www.jstor.org/pss/3767849
HSL18193
Turone F
Italian police investigate GSK Italy for bribery
BMJ 2003;326:(7386):413
http://www.bmj.com/cgi/content/extract/326/7386/413/a
HSL18225
Top 10 drugs
Australian Prescriber 2003;26:(1):4
http://www.australianprescriber.com/magazine/20/4/artid/231
HSL18226
Fogg S
Informing the consumer
Aust Prescr 2003;26:2-3
http://www.australianprescriber.com/magazine/26/1/2/3/
HSL18227
Sweet M
Gabapentin documents raise concerns about off-label promotion and prescribing
Aust Prescr 2003;26:18-9
http://www.australianprescriber.com/magazine/26/1/18/9
HSL18228
Greed and Gabapentin
Aust Prescr 2003;26:19
http://www.australianprescriber.com/magazine/26/1/artid/640/
HSL19048
Schwartz LM, Woloshin S.
On the prevention and treatment of exaggeration.
J Gen Intern Med 2003;18:(2):153-4
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1494822/?tool=pubmed
HSL19391
Berndt E, Pindyck R, Azoulay P
Consumption externalities and diffusion in pharmaceutical markets: antiulcer drugs
The J Ind Econ 2003;51:(2):243-270
http://www.nber.org/papers/w7772
HSL19517
Grande D
Cost and Quality of Industry-Sponsored Meals for Medical Residents
JAMA 2003;290:(9):1150-1151
http://jama.ama-assn.org/content/290/9/1150.3.full
HSL19857
Burton B, Rowell A
Disease Mongering
PR Watch 2003;10:(1):
http://www.prwatch.org/prwissues/2003Q1/monger.html
HSL19858
Burton B, Rowell A
From Patient Activism to Astroturf Marketing
PR Watch 2003;10:(1):5
http://www.prwatch.org/prwissues/2003Q1/astroturf.html
HSL19859
Rowell A, Burton B
Clinically Suppressed
PR Watch 2003;10:(1):7
http://www.prwatch.org/prwissues/2003Q1/suppressed.html
HSL17381
Schwab D
No letup in drug industry debate
Star-Ledger 2002 Dec 29
Page 153 of 206 pages ‹ First < 151 152 153 154 155 > Last ›
